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Summary. Inflammatory Bowel Disease (IBD), which includes both Crohn’s Disease (CD) and Ulcerative 
Colitis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Extraintestinal 
manifestations (EIMs) are common in patients with IBD, and occur in 6%-47% of patients with CD or UC. 
EIMs can involve organs other than the gastrointestinal tract such as skin, eyes, joints, biliary tract, and kidneys. 
Renal and urinary involvement particularly occurs in 4-23% of patients with IBD. Among the renal complica-
tions of IBD, secondary amyloidosis (AA-type, AAA) is a rare but serious complication. Renal amyloidosis has 
been proven to be the most common lethal manifestation of IBD-associated amyloidosis, since renal involve-
ment rapidly leads to end-stage renal failure. A few studies suggest that AAA is more prevalent in CD than 
in UC, mainly occurring in male patients with an extensive, long-lasting, and penetrating disease pattern. The 
therapeutic approaches of IBD-associated AAA are based both on control of the chronic inflammatory process 
that causes the production and storage of serum amyloid A (SAA), which is a precursor of the amyloid, as well as 
on destabilizing amyloid fibrils so that they can no longer maintain their β-pleated sheet configuration; however, 
in patients with end-stage renal disease, the only therapeutic options still available are hemodyalisis and renal 
transplantation. Whether effective treatment exists for AAA remains controversial. 
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Progress in Nutrition 2017; Vol. 19, N. 1: 5-13 - DOI: 10.23751/pn.v19i1.4460                   © Mattioli 1885
  R e v i e w
Introduction
Inflammatory Bowel Disease (IBD), which in-
cludes both Crohn’s Disease (CD) and Ulcerative Coli-
tis (UC), is a chronic idiopathic inflammatory disorder 
affecting the gastrointestinal tract. (1). CD and UC af-
fect more than 1 million people in the United States, 
with thousands of new diagnoses annually (2,3). The 
natural history of CD and UC is characterized by re-
peated episodes of inflammation and ulceration of the 
bowel. This results in complications implying a worse 
quality of life and significant healthcare costs, due to 
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hospitalization, surgery and an escalation of therapy 
(4-7). Extraintestinal manifestations (EIMs) are com-
mon in patients with IBD, and occur in 6-47% of pa-
tients with CD or UC (8). EIMs can involve organs 
other than the gastrointestinal tract such as skin, eyes, 
joints, biliary tract, and kidneys (9). Renal and urinary 
involvement particularly occurs in 4-23% of patients 
with IBD (10). Several factors may be responsible for 
renal involvement.
Primary systemic affection by the disease itself 
or secondary complications such as chronic inflam-
mation, malnutrition, and side effects of therapeutic 
agents may trigger the emergence of renal dysfunc-
tion. In general, renal manifestations, like other EIMs, 
tend to follow the clinical course of IBD and may have 
a high impact on quality of life, morbidity, and even 
mortality of patients (9).
Among the renal complications of IBD, second-
ary amyloidosis (AA-type, AAA) is a rare but serious 
complication. Renal amyloidosis has been proven to be 
the most common lethal manifestation of IBD-associ-
ated amyloidosis, since renal involvement rapidly leads 
to end-stage renal failure (11).
In this article the authors review the available data 
on secondary amyloidosis and IBD, focusing on preva-
lence, risk factors, clinical presentation and therapeutic 
measures.
Prevalence of amyloidosis in inflammatory bowel 
disease
Amyloidosis is a term applied to a heterogeneous 
group of rare diseases characterized by extracellular 
deposition of amyloid, causing target-organ dysfunc-
tion and a wide range of clinical symptoms (12). All 
forms of amyloidosis are characterized by the deposi-
tion of extracellular fibrils in various tissues.
These fibrils are the result of the misfolding of a 
protein from its normal α-helical configuration
into a β-pleated sheet. The structure of the 
β-pleated sheet allows the binding of Congo red stain, 
which emits a characteristic apple-green birefringence 
under polarized light. 
The symptoms of the disease depend on the or-
gan involved, and include nephritic syndrome, hepa-
tosplenomegaly, congestive heart failure, carpal tun-
nel syndrome, gastrointestinal (GI) symptoms and 
macroglossia (13). Amyloidosis is clinically classified 
into several types depending on the precursor of the 
amyloid fibril. The disease involves amyloid fibrils 
formed in vivo by 27 different types of protein (14). 
In immunoglobulin-light-chain-related (AL) amy-
loidosis (also called primary amyloidosis), an under-
lying monoclonal plasma-cell disorder produces the 
constituents of the deposits, which are the variable 
regions of the immunoglobulin light chains. In AAA, 
by contrast, the amyloidogenic precursor is a normal 
acute-phase reactant called serum amyloid A (SAA), 
which is produced as the result of chronic infection or 
inflammation. In this connection, AAA is the repre-
sentative systemic condition that develops in patients 
with chronic inflammatory diseases such as rheuma-
toid arthritis, juvenile idiopathic arthritis, ankylosing 
spondylitis, IBD, familial periodic fever syndrome, and 
chronic infections (15-18). Epidemiological data for 
AAA, extrapolated from autopsy records in Western 
nations, have indicated that the prevalence varies from 
about 0.5% to 0.86% according to environmental risk 
factors and geographical clustering (19,20).
Little is known about the prevalence of AAA in 
patients with IBD.
In the first study, performed by Greenstein and 
coworkers (18), the authors evaluated the prevalence of 
AAA in 3050 patients with IBD (1709 with CD, and 
1341 with UC), enrolled at the Mount Sinai Hospital, 
between 1960 and 1985. The study showed that 0.9% 
(n=15) of CD patients and 0.07% (n=1) of UC patients 
were affected by AA Amyloidosis (in total, 16 patients).
Eleven of the patients with CD who had amy-
loidosis also? had ileocolitis, 2 colitis, and 2 ileitis; 
these figures represent a frequency within each group 
of 1.6%, 0.6%, and 0.3%, respectively. AAA was thus 
associated 4.4 times more often with CD of the colon 
than with pure small bowel disease. In this study the 
authors added to this group of 15 patients the 5 cases 
of CD that were originally reported by Werther and 
coworkers in 1960 (21), plus another 4 (2 with UC and 
2 with CD) who have been seen since 1985, making a 
total of 25 patients in this series (22 with CD and 3 
with UC). There was a striking male preponderance 
(16 of 22) among patients with CD, although 2 of the 
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3 patients with UC were females. AAA was diagnosed 
at a mean age of 40 years, about 15 years after the onset 
of CD. Nephrotic syndrome developed in 15 patients 
with CD and was accompanied by renal failure, the 
major contributor to mortality, in 10 of the 13 patients 
who died. AAA may be associated with suppurative or 
other EIMs of IBD. 
Wester and coworkers (22), successively described 
18 patients with IBD and AAA, with special emphasis 
on clinicopathological features and site relationships. 
Fifteen of the 18 patients had CD, 1 had UC, 1 had 
UC preceding CD, and 1 had indeterminate colitis. 
There was a male preponderance of 13:5 = 2.6. Five of 
the patients had AAA at the time of diagnosis of IBD. 
Median time from diagnosis of IBD to AAA was 4 
years, whereas AAA was diagnosed within 5 years of 
onset of IBD in 11 patients. Thirteen of the patients 
had suppurative complications, and 12 had extraint-
estinal manifestations. Interestingly, ten patients had 
been treated by renal transplantation. After 15 years 
of follow-up, the survival rate was 60%. These results 
highlighted the previous impression of an approxi-
mately 3-fold increased preponderance in males, with 
at least a 10-fold increased frequency in CD compared 
with UC, and with a possible relationship to suppura-
tive complications and extraintestinal manifestations, 
as well as an increased risk of having bowel resection. 
More recently, Serra and coworkers (23) evalu-
ated the prevalence of AAA in a large IBD cohort at 
a referral centre, describing its clinical characteristics 
and outcome. In this study patients diagnosed with 
AAA were identified among 1006 IBD patients in-
cluded in the IBD database of the centre, and among a 
total of 1006 IBD patients, 5 cases of amyloidosis were 
identified, all of them with CD, resulting in a preva-
lence of 0.5% for IBD and 1% for CD. With regard 
to the outcome of the disease, two patients died after 
developing renal failure, but interestingly two patients 
were treated with anti-TNF agents, showing a clinical 
improvement of their AAA.
Furthermore, another Spanish study enrolling 
4018 IBD patients found that 17 patients developed 
AAA, with a prevalence of 0.63% in CD, 1% in inde-
terminate colitis, and 0.06% in UC (24).
In summary, the available data from the litera-
ture show that the prevalence of AAA is about 0.5% 
in IBD patients (with the sole exception of Wester’s 
cohort). In most cases, AAA involves CD patients, 
whose prevalence accounts for about 0.7-1%.
However, the aforementioned studies present sev-
eral methodological limitations: firstly, all the studies 
mentioned are retrospective; furthermore, all the avail-
able studies are based on selected cohorts from tertiary 
referral centers (thus showing a selection bias). Only 
Lowdell and coworkers (25) prospectively evaluated 
the incidence of AAA in a cohort of IBD patients (77 
with CD, 97 with UC), through rectal biopsy and the 
study of renal function, but no new diagnosis of AAA 
was reported.
Clinical presentation
Historically, the diagnosis of AAA in IBD pa-
tients has mainly been autoptic (26), as reported firstly 
by Werther and coworkers (21). However, since the 
early 1980s the diagnosis of AAA has also been re-
ported in living patients with active IBD (18,22-24). 
With regard to the clinical presentation of AAA, 
it depends on the amount of amyloid deposits in the 
affected organs. At the beginning of the disease, the 
symptoms are unspecific, with the onset of weakness, 
weight loss, headache or syncope; however, in the ad-
vanced stages of the disease, organ-specific symptoms 
occur. The most common clinical manifestation of 
AAA in IBD patients is renal disease, often appear-
ing as nephritic proteinuria; however, in the end-stage 
disease glomerular involvement may cause the onset of 
renal failure and uremia. A particular feature of renal 
AAA is maintenance of the regular size of the kidneys, 
together with the occurrence of hypotension instead 
of more common hypertension. In the aforementioned 
studies (18, 22-24) the occurrence of proteinuria and/
or renal failure was reported in about 86% of the pa-
tients.
GI involvement represents the second most com-
mon clinical presentation of AAA in IBD patients, in 
order of frequency, as reported in the aforementioned 
studies. However, these studies show that only about 
6% of IBD patients presented with gastrointestinal 
complaints, and these patients could be totally asymp-
tomatic or present with severe malabsorption (27).
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Myocardial involvement, although rare, repre-
sents, in order of frequency, the third most common 
clinical presentation of AAA in IBD patients, thus 
provoking the insidious onset of congestive heart fail-
ure, conduction disorders and arrhythmias (27).
Macroglossia is usually infrequent in AAA in 
IBD patients, because it is a peculiar clinical manifes-
tation of primary amyloidosis. Furthermore, the liver, 
spleen and thyroid may also be involved in AAA in 
IBD patients (27).
The suspicious of the onset of AAA in IBD pa-
tients should be raised in all patients presenting with 
proteinuria and renal failure, or in patients with ab-
normal malabsorption not attributable to underlying 
IBD. Diagnostic confirmation of AAA should be ob-
tained through demonstration of amyloid deposits in 
the affected tissues. Liver and renal biopsy presents 
present? an optimal diagnostic yield, but may lead to 
several complications. Therefore the diagnostic choice 
of biopsy of abdominal fat (sensitivity 60-80%) or rec-
tal mucosa (sensitivity 50-70%) (28) seems to be more 
reliable; however, in the latter cases, if the samples ob-
tained present a negative result, biopsy should be per-
formed in the target organ.
Risk factors for the development of AA Amyloidosis 
in IBD patients
On the basis of the reported data (18,22-24), CD 
appears to be more frequently associated with AAA 
than UC. In this connection, considering that AAA 
arises from storage of an acute phase reactant like se-
rum amyloid A (SAA), it seems reasonable to think 
that this disease will develop in patients with long-
standing disease and with poor control of the inflam-
mation. This phenomenon seems to be more frequent 
in CD, since the clinical course of CD appears to be 
more indolent and insidious, as patients with severe 
endoscopic lesions are often asymptomatic, whereas 
UC usually presents with severe acute flares, although 
the reason of this discrepancy in the incidence of AA 
Amyloidosis in both the disease is not yet clear. Fur-
thermore, another possible explanation of this discrep-
ancy may be the fact that severe UC often resolves with 
proctocolectomy, whereas surgery often not eliminate 
the inflammatory process occurring in CD (27). 
Further specific features of AAA in IBD patients 
are male preponderance, with a sex ratio of 3:1, and the 
presence of an extensive underlying IBD (18,22-24). 
Table 1. Clinical studies evaluating prevalence and features related to IBD-associated amyloidosis
Study (authors,  Patients (n) Male/Female Cases of Localization Median Abdominal Extraintestinal 
reference)  ratio (%) Amyloidosis  (%) follow-up complication (%) 
   (n) and   (Years) (%) 
   prevalence (%)
Greenstein and  3050  73% vs. 27% 16 (0,05%);  64% ileocolic 15 68% 54% 
coworkers (18)   15 with CD;  (14% with 
   1 with UC upper CD)
Wester and  500 81% vs. 19% 18 (3%); 62% ileocólica 4 69% 66% 
coworkers (22)   16 with CD;   (31% with 
   1 with UC; 1  upper CD) 
   with IC 
Serra and  1006 80% vs. 20% 5 (0,5%), 100% ileocolic 15 80% 60% 
coworkers (23)    all with CD 
Pèrez – Martinez  4018 70% vs. 30% 17 (0,4%);  60% (13%  9 53% 47% 
and coworkers (24)   15 with CD,  with upper  
   1 with UC,  CD) 
   1 with IC 
Abbreviations: IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s Disease; IC: indeterminate colitis
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With specific regard to CD-associated AAA, more 
than two-thirds of the reported cases of CD-associat-
ed AAA presented with both colonic (and often pan-
colonic) and ileocolonic disease, and interestingly with 
an upper GI involvement in almost 15% of cases. Fur-
thermore, the pattern of the CD associated-AAA was 
prevalently a penetrating one, with the concomitant 
occurrence of intra-abdominal or perianal abscesses 
and/or fistulae in 70-80% of patients (27).
The occurrence of further EIMs during the course 
of the disease in IBD patients with AAA was slightly 
higher than usual: onset of EIMs in this subset of pa-
tients was about 50-60%.
Finally, AAA usually appears in the context of a 
longstanding IBD; indeed, the onset of IBD-associat-
ed AAA was found to occur almost ten years after the 
onset of underlying IBD, and this phenomenon could 
be related to the longstanding inflammatory process of 
the disease (27).
Interestingly, further inflammatory chronic dis-
eases associated with AAA may coexist with AAA-
associated IBD, like rheumatoid arthritis, juvenile id-
iopathic arthritis, familial periodic fever syndrome, etc. 
Therefore it is an important diagnostic challenge to 
exclude the occurrence of these diseases when AAA-
associated IBD is suspected (18,22,23).
In summary, AAA is more frequent in male CD 
patients, with longstanding, penetrating and extensive 
disease, often associated with EIM, although clear 
evidences about this AAA-associated risk factor are 
not yet available. However, the emerging concept of 
mucosal healing as a therapeutic target in IBD pa-
tients, using immunosuppressive and biological (e.g. 
anti-Tumor Necrosis Factor alpha, anti-TNF) drugs, 
could lead to a dramatic change in the prevalence and 
prognosis of IBD complications, such as AAA (27).
Prognosis
As previously highlighted, during the last few de-
cades it has been observed that prognosis of IBD-as-
sociated AAA has dramatically changed, considering 
that AAA, initially mainly reported through autoptic 
diagnosis, successively became a real nosographic en-
tity in IBD patients (27). 
This could be due to the current optimal manage-
ment (both medical and surgical) of IBD, the high 
index of clinical suspicion of AAA since the first epi-
demiological studies on AAA (22), and increased at-
tention to knowledge of the natural history of IBD, 
with particular attention to the nutritional status of 
IBD patients, early diagnosis and prevention of IBD-
associated complication and better awareness of IBD-
associated drug adverse events (27).
Interestingly, a study performed by Weterman 
and coworkers showed that AAA has disappeared as 
a leading cause of mortality in CD patients; this could 
be due to the better medical and surgical management 
of these patients (29).
The best related prognostic factor of survival in 
IBD-associated AAA proved to be serum creatinine, 
as an expression of the level of renal failure (30). In the 
case of end-stage renal failure related to AAA, renal 
transplantation may be considered the best therapeutic 
option, thus dramatically reducing the mortality rate 
(31). However, patients with IBD-associated AAA 
present a higher mortality rate than patients without 
AAA, and severe infections and hemorrhage are re-
ported to be the most frequent causes of mortality af-
ter end-stage renal failure (18,29,32).
With regard to the survival rate in this subset of 
patients, few data are available. It has been estimated 
that the median survival rates proves to be approxi-
mately 89% at five years, and 60% at fifteen years of 
follow-up (22).
Figure 1. Etiologic disease-related factors involved in pathoge-
nesis of IBD-associated amyloidosis
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Therapy
The therapeutic approach of IBD-associated 
AAA is primarily based on control of the inflamma-
tory process that causes production and storage of the 
SAA, which is a precursor of amyloid (27).
In this context, the role of surgery appears con-
troversial. Even if clinical improvement of the disease 
is observed in some patients after bowel resection, the 
fact that AAA has been diagnosed after surgery does 
mean that the latter by itself is decisive for preven-
tion or resolution of AAA (33-36). Furthermore, sev-
eral authors have observed a higher mortality of IBD 
patients with AAA after surgery, without a clinical 
improvement in AAA, considering that such patients 
present a higher surgical risk, due to the occurrence of 
renal failure, hemorrhage or severe infections (18,37). 
Based on these considerations, it seems reasonable to 
consider the surgical option as a secondary therapeutic 
option in selected cases, e.g. after the failure of medical 
therapies, or in the case of penetrating and stricturing 
disease (18,25,36-38).
On the other hand, the use of drugs acting di-
rectly against the process of development of amyloi-
dosis has been shown to be helpful. In this context, 
colchicine has proved to be the most effective drugs. In 
this connection, the effectiveness of this drug in other 
types of secondary amyloidosis (for example, amyloi-
dosis associated with familial Mediterranean fever) has 
been demonstrated by a reduction in proteinuria, nor-
malization of renal function, and improvement in the 
survival rate of affected patients (38-41).
We recommend the early use of colchicine, be-
fore the onset of renal failure. Another drug commonly 
used in AAA is dimethylsulfoxide, also used in other 
types of secondary amyloidosis; it has appeared to be 
helpful in maintenance of normalization of the serum 
creatinine and in reduction of proteinuria, after one 
year of treatment (42).
More recently, anti-TNF alpha drugs have also 
proved effective in the treatment of AAA, through re-
duction in proteinuria and normalization of the renal 
function. Several studies have shown the capacity of 
this drug to reduce SAA levels, probably because pro-
duction and storage of SAA are enhanced by pro-in-
flammatory cytokines, such as TNF-alpha; therefore, 
considering the efficacy of these drugs in the treatment 
of both IBD and AAA, anti-TNF alpha agents may 
play a pivotal role in elective treatment of IBD-asso-
ciated AAA. Encouraging results regarding the use of 
anti-TNF alpha agents in AAA treatment associated 
which chronic inflammatory disease come from several 
studies carried out in the setting of rheumatic disease 
(43-56). Interestingly, in a recent report, tocilizumab 
was found to be effective in amyloidosis-associated 
kidney disease secondary to IBD (57).
Further therapeutic approaches target amyloid 
deposits directly, by destabilizing amyloid fibrils so 
that they can no longer maintain their β-pleated sheet 
configuration. Studies on compounds that bind serum 
amyloid P component (SAP), an essential constituent 
of all forms of amyloid deposits that constitute 5 to 
10% of their weight, suggest the possibility not only 
of depleting SAP from the fibril but also of causing 
regression of amyloid deposits (58,59)
Dember and colleagues followed a similar ap-
proach, aiming to destabilize the glycosaminoglycan 
backbone of amyloid deposits. Eprodisate binds to 
glycosaminoglycan-binding sites on amyloid fibrils 
and in principle can destabilize them in tissues, there-
by causing regression of amyloidosis; in addition, it has 
the potential to prevent the formation of new amyloid 
deposits. 
The risk of worsening renal function and the 
rate of decline in creatinine clearance were shown to 
be lower in patients who received eprodisate than in 
those who received placebos. However, no effect was 
seen on the progression to end-stage renal disease or 
death (60).
Finally, in patients with end-stage renal disease, 
the only therapeutic options still available are hemody-
alisis and renal transplantation (27).
Conclusion and recommendations
AAA is a clinical challenge for clinicians manag-
ing IBD patients. A few studies suggest that AAA is 
more prevalent in CD than in UC, mainly occurring in 
male patients with an extensive, long-lasting, and pen-
etrating disease pattern. The therapeutic approaches of 
IBD-associated AAA are both based on control of the 
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chronic inflammatory process that causes production 
and storage of SAA, which is a precursor of amyloid, as 
well as on destabilizing amyloid fibrils so that they can 
no longer maintain their β-pleated sheet configuration; 
however, in patients with end-stage renal disease, the 
only therapeutic options still available are hemodyalisis 
and renal transplantation. Whether effective treatment 
exists for AAA remains controversial.
There are reports suggesting that AAA improves 
after surgical treatment, while other reports show sig-
nificant morbidity and even mortality after surgery; 
colchicine and dimethylsulfoxide have been used, 
showing significant efficacy in reducing the rate of 
amyloid deposition by preventing the progression of 
the inflammatory process at the neutrophil level. More 
recent reports have suggested the efficacy of TNF in-
hibitors in treating CD-associated AAA; in particular, 
treatment of renal AAA with infliximab has shown 
improvement in renal function and proteinuria and a 
decrease in SAA levels. Although infliximab has prov-
en its efficacy in the treatment of CD, its consecutive 
administration in CD-associated renal AAA cannot 
restore the previous damage, but targets the deteriora-
tion of further damage in the kidneys and the delay of 
renal injury (61). Finally, further studies could evalu-
ate the role of eprodisate, which destabilizes the gly-
cosaminoglycan backbone of amyloid deposits, in this 
subset of patients.
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